Seventeen new medicines recommended for approval
EMA’s human medicines committee (CHMP) recommended seventeen medicines for approval at its December 2024 meeting. This brings the total number of medicines recommended for approval in 2024 to 114.
The CHMP recommended granting a marketing authorisation for Andembry* (garadacimab), for the prevention of recurrent attacks of hereditary angioedema, a rare, potentially life-threatening disorder characterised by attacks of cutaneous and submucosal swelling.
The committee adopted a positive opinion for Beyonttra* (acoramidis), for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy, a disease that affects the heart muscle…
